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Abstract
Background
There is no evidence-based definition of the temperature limit defining fever (TLDF) in chil-
dren with neutropenia. Lowering the TLDF is known to increase the number of episodes of
fever in neutropenia (FN). This study aimed to investigate the influence of a lower versus
standard TLDF on diagnostics and therapy.
Methods
In a single pediatric cancer center using a high standard TLDF (39˚C tympanic-temperature)
patients were observed prospectively (NCT01683370). The effect of applying lower TLDFs
(range 37.5˚C to 38.9˚C) versus 39.0˚C on these measures was simulated in silicon.
Results
In reality, 45 FN episodes were diagnosed. Of 3391 temperatures measured, 193 were
39.0˚C, and 93738.0˚C. For persisting fever24 hours, additional blood cultures were
taken in 31 (69%) episodes in reality. This number decreased to 22 (49%) when applying
39.0˚C, and increased to 33 for 38.0˚C (73%; plus 11 episodes; plus 24%). For persisting
fever48 hours, i.v.-antibiotics were escalated in 25 (56%) episodes. This number
decreased to 15 (33%) when applying 39.0˚C, and increased to 26 for 38.0˚C (58%; plus 11
episodes; plus 24%). For persisting fever120 hours, i.v.-antifungals were added in 4 (9%)
episodes. This number increased to 6 (13%) by virtually applying 39.0˚C, and to 11 for
38.0˚C (24%; plus 5 episodes; plus 11%). The median length of stay was 5.7 days (range,
0.8 to 43.4). In 43 episodes with hospital discharge beyond 24 hours, applying 38.0˚C led to
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discharge delay by12 hours in 24 episodes (56%; 95% CI, 40 to 71), with a median delay
of 13 hours, and a cumulative delay of 68 days.
Conclusion
Applying a low versus standard TLDF led to relevant increases of diagnostics, antimicrobial
therapy, and length of stay. The differences between management in reality versus simply
applying 39.0˚ as TLDF reflect the important impact of clinical assessment.
Introduction
In children with cancer, fever in chemotherapy-induced severe neutropenia (FN) is the most
frequent potentially lethal complication and the leading cause of emergency hospitalization
[1]. Empirical therapy with broad-spectrum antibiotics, usually given intravenously in an in-
house setting, are routine measures for pediatric FN. They have led to a reduction of the FN
associated mortality below 1% in developed countries [2]. However, there is no international
consensus on temperature-limits defining fever (TLDF) for children with chemotherapy-
induced severe neutropenia, despite its relevance for the clinical diagnosis and management of
FN [1,3,4]. A review of the current literature shows a wide range of TLDF used clinically from
37.5˚C to 39.0˚C [5–7]. Through this inconsistency between different centers, the diagnosis of
FN is made at varying temperatures. At our center in Bern, with a historically established high
TLDF of 39˚C ear-temperature, it has recently been shown that this high TLDF is efficacious
in reducing the number of FN diagnosis and thus overtreatment. Lowering this limit would
have led to additional FN diagnosis [7].
Not only the diagnosis of FN and the initial therapy are influenced by the TLDF applied,
but also the clinical measures of diagnostics and treatment during the whole hospitalization
for FN are determined by the TLDF applied. Those measures include for example the number
of blood cultures taken, the time-point of escalating empirical antibiotic therapy to a broader
spectrum, or the time point of adding on empirical antifungal treatment in case of persisting
fever [1]. Moreover, it influences the time point of hospital discharge and thus the length of
hospitalization. These measures not only have a direct impact on the individual patient and its
quality of life but also on resource utilization and treatment costs [8].
Based on the historically established clinical use of a high TLDF of 39˚C in Bern [7,9] this
prospective single-center study aimed to assess the influence of virtually lowering the TLDF of
39˚C ear-temperature on diagnostic measures, time-points of treatment escalation and hospi-
tal discharge after FN diagnosis.
Patients and methods
Study design
This prospective observational study was conducted in a single pediatric cancer center that
routinely uses a high TLDF (39.0˚C tympanic temperature, LimitStandard). The intervention of
virtually lowering the TLDF and its effects on FN related measures were simulated in silicon
using commercially available software. Therefore, diagnosis of FN, initial treatment of the
study patients and their clinical management after FN diagnosis were not influenced by study
participation.
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Abbreviations: ANC, Absolute neutrophil count;
BC, Blood culture; CBC, Complete blood count; CI,
Confidence interval; FN, Fever in (chemotherapy-
induced severe) neutropenia; IQR, Interquartile
Range; LimitLow, Hypothetically applied lower
temperature limit defining fever; LimitStandard,
Standard temperature limit defining fever
(39.0˚C); TLDF, Temperature limit defining fever.
The study was conducted in accordance with the Declaration of Helsinki. The Institutional
Review Board (Ethikkommission der Universita¨tskinderkliniken Bern, “Gesuch 1205”) had
approved the study protocol and the trial had been registered at www.clinicaltrials.com
(NCT01683370) before starting patient accrual. Written informed consent was obtained from
the patients, if able to judge, and from their legal guardians prior to study entry.
The effects of virtually lowering the TLDF on the rate of FN diagnosis itself have been pub-
lished elsewhere [7].
Patients
Patients aged 1 to 17 years with cancer who were treated at the Department of Pediatrics, Uni-
versity of Bern, Inselspital, Bern, Switzerland, and who required chemotherapy for2 months
at time of recruitment were eligible.
Patients were off study when informed consent was withdrawn and when chemotherapy
was completed (2 weeks after last dose and absolute neutrophil count (ANC) >0.5 G/L).
Patients were recruited from August 11, 2012 to May 31, 2013, while follow-up was closed on
August 07, 2013.
Routine clinical management, including FN
Patients were treated with chemotherapy, including myeloablative therapy followed by autolo-
gous peripheral stem cell transplantations, or multimodal therapy, according to internationally
established protocols. Except for standard Pneumocystis jirovecii prophylaxis, no primary anti-
microbial prophylaxis was used [10,11]. Secondary antifungal or antiviral prophylaxis was
introduced after repeated infections.
FN was diagnosed when a patient with severe chemotherapy-induced neutropenia devel-
oped fever. Fever was defined as a single temperature of39.0˚C (LimitStandard), measured in
the ear by infrared tympanic thermometry using the commercially available Braun Thermo-
scan 5 (IRT 4520; Braun GmbH, Kronberg, Germany) [12]. This TLDF corresponds to 39.1˚C
core temperature, and to 38.4˚C axillary temperature (Nimah, PCCM, 2006). Severe neutrope-
nia was defined as an ANC0.5 G/L or1.0 G/L and expected to decline. If clinically indi-
cated, the treating physician was free to diagnose FN at lower temperatures [2,9,13].
Routine clinical measures after FN diagnosis included emergency hospitalization, taking
blood cultures (BC) from the central venous access device before starting empirical intrave-
nous broad-spectrum antibiotics, usually ceftriaxone plus amikacin and antipyretics [14]. Fur-
ther details on clinical management have been published [2,9].
For persisting fever despite treatment, the following clinical rules were usually applied:
every 24 hours additional BC were taken; after 48 hours the empirical intravenous antibiotics
were escalated, usually to meropenem and vancomycin, for a broader antimicrobial coverage;
and after 120 hours, empirical intravenous antifungals were added [15]. Patients were dis-
charged when they had been afebrile for48 hours, were clinically well, had a rising leukocyte
count and/or ANC irrespective of absolute values, and had negative blood cultures.
Data management, outcome measures and analysis
Results of all temperature measurements and information on the diagnostic and therapeutic
measures after FN diagnosis studied here were extracted from patients’ charts and directly
entered into Excel-spreadsheets by an experienced pediatric oncology nurse. This information
was checked for plausibility and, in case of doubt, conformity with patient charts by two senior
pediatric oncologists (E.S.-G., R.A.A.).
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The analysis was performed by a pediatric trainee (S.W.) under supervision of the senior
author (R.A.A). The following outcome measures, all related to persistent fever as described
above, were analyzed: episodes with at least one additional BC taken after start of antibiotics;
with escalation of antibiotic coverage, with start of empirical antifungals, and with hospital dis-
charge delayed12 hours because of fever. The measures determined in reality were com-
pared with measures virtually determined by strictly applying the rules for persisting fever
described above, using LimitStandard (TLDF 39.0˚C), and different settings for LimitLow, (TLDF
ranging from 37.5˚C to 38.9˚C) [7,16]. Four FN episodes that had been diagnosed below
39.0˚C for clinical reasons and in which 39.0˚C was never reached were excluded from the
analysis of delayed hospital discharge, as the in silico simulation relied on FN diagnosis made
at39.0˚C [7]. One further FN episode was excluded from this specific analysis due to early
discharge before 24 hours because of a low risk of complications [17–19].
Compared to the previously published results on the primary study aims [7], two additional
FN episodes are reported here. This results from splitting up one FN episode with continued
oral antimicrobial therapy for osteomyelitis over six months into three separate FN episodes.
Formally, this episode fulfilled the study criteria for a single episode because of continued
antimicrobial therapy, and was treated as such for the analysis focused on FN diagnosis [7].
In reality, however, the patient was hospitalized three times for FN, with outpatient periods
exceeding one month between hospitalizations. Analyzing these hospitalizations as separate
FN episodes seemed to be more adequate for the outcomes reported here.
Statistics
Due to non-normally distributed data, median, interquartile range (IQR), and range were cal-
culated. Proportions with exact 95% confidence intervals (CI) were calculated [20]. The sample
size had been determined to result in an adequate power for analysis of the primary efficacy
aim of the study, the number of FN episodes diagnosed [7], and thus was not adapted to fulfill
specific power requirements for the secondary aims described here.
The in silicon simulation by virtually applying different TLDFs was performed in Excel 2010
spreadsheets (Microsoft, Redmond, Washington, USA), and statistical analyses in R 3.2.3
(R Foundation for Statistical Computing, Vienna, Austria). P-values <0.05 were considered
significant.
Results
Patients, FN episodes, temperature measurements and complete blood
counts (CBC)
Patients were recruited from August 2012 to May 2013. Of 40 patients potentially eligible, 39
(98%) gave informed consent and thus participated in the study. Median age at recruitment
was 7.4 years (range, 1.2 to 16.7), and 16 (41%) were girls. The distribution of cancer diagnosis
and further details about the therapy and interventions have been published elsewhere [7].
During a cumulative duration of 289 months (24 years) of chemotherapy, 45 FN episodes
were diagnosed in 20 patients (maximum, 6 episodes per patient). Of these, 12 (27%) episodes
had been diagnosed by the treating physician at temperatures below 39.0˚C for clinical reasons
[7].
During the FN episodes (cumulative duration, 329 days) 3391 temperature measurements
were recorded (median, 56 per episode; IQR, 40 to 83; range, 7 to 401). The median tempera-
ture was 37.3˚C (IQR, 36.8˚C to 38.0˚C; range, 35.0˚C to 41.2˚C) and 193 measurements
(5.7%) were39.0˚C (LimitStandard, Fig 1). Furthermore, 318 CBCs were performed (median,
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6 per episode; IQR, 5 to 7; range, 2 to 32). The ANC was0.5 G/L in 208 CBCs (65%), 0.5 to
1.0 G/L in 29 (9%), >1.0 G/L in 58 (18%), and unknown in 23 (7%, Fig 2).
Additional blood cultures after start of antibiotics
In reality, 122 BC were taken in total, with a median of 2 BC per FN episode (range, 1 to 11).
Of these, 45 were BC taken at the initial presentation for FN, and 77 were additional BC taken
after start of antibiotics in 31 of 45 episodes (69%; 95% CI, 53% to 82%), usually for persisting
fever. Virtually applying LimitStandard (39.0˚C) as TLDF for persisting fever, 43 additional BC
in 22 episodes (49%; 95% CI, 34% to 64%; minus 9 episodes compared to reality) remained.
Virtually applying a range of LimitLow, this number increased to 68 additional BC in 29 epi-
sodes (64%; minus 2) for 38.5˚C, to 103 additional BC in 33 episodes (73%; plus 2) for 38.0˚C,
and to 148 additional BC in 38 episodes (84%; plus 7) for 37.5˚C (Fig 3, Table 1).
Of the 122 BC, 10 were reported positive, but 1 was considered false positive (contamina-
tion with Micrococcus species). Thus, in 9 of the 45 FN episodes (20%; 95% CI, 10% to 35%),
bacteremia was detected.
The species detected were: Klebsiella pneumonia in 2 episodes, Actinomyces odontolyticus
plus S. viridans in one episode and Enterococcus faecium, Staphylococcus aureus, coagulase-neg-
ative Staphylococcus, Streptococcus viridans, Fusobacterium species and Moraxella catarrhalis in
one episode each.
In 6 FN episodes the initial BC was reported positive. In 3 episodes the initial BC showed
no bacterial or fungal growth but a BC taken after start of antibiotic therapy revealed bacter-
emia (one each with coagulase-negative Staphylococcus, E. faecium and S. aureus). The temper-
ature at taking the respective BC was below LimitStandard in two episodes (38.6˚C and 37.9˚C,
respectively), andLimitStandard in one.
Fig 1. Temperature measurements during FN (n = 3391).
https://doi.org/10.1371/journal.pone.0193227.g001
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Escalation of empirical antibiotics
In reality, intravenous antibiotics were given for a median of 5.7 days (range, 1 to 43). They
were escalated in order to achieve broader coverage after a median of 49 hours (range, 7 to
112) in 22 (49%; 95% CI, 34% to 64%) FN episodes, usually for persisting fever48 hours. Vir-
tually applying LimitStandard (39.0˚C) as TLDF for persisting fever resulted in escalation after a
Fig 2. Absolute neutrophil counts in blood counts during FN (n = 295). Displayed are the absolute neutrophil counts up to 1 G/L.
https://doi.org/10.1371/journal.pone.0193227.g002
Fig 3. Proportion of FN episodes with modifications of management for persisting fever, in reality and virtually
according to different TLDF. Displayed are the proportions, plus their 95% CI as vertical lines, of FN episodes with
additional blood cultures taken, with an escalation of antibiotics and with adding on antifungals, respectively, for
persisting fever. Squares indicate management in reality, and circles indicate management simulated, strictly applying
LimitStandard and different LimitLow.
https://doi.org/10.1371/journal.pone.0193227.g003
Influence of different fever definitions during neutropenia in children with cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0193227 February 20, 2018 6 / 11
median of 74hours in 15 episodes (33%; 95% CI, 20% to 49%; minus 7 episodes compared to
reality). Virtually applying a range of LimitLow increased the number of such episodes to 22
(49%; 95% CI, 34% to 64%, as in reality) for 38.5˚C, to 26 (58%; 95% CI, 42% to 72%, plus 4)
for 38.0˚C, and to 34 (76%; 95% CI, 60% to 87%, plus 12) for 37.5˚C (Fig 3, Table 1).
Addition of empirical antifungal therapy
In reality, an intravenous empirical antifungal therapy was added after a median of 177 hours
(7.4 days; range, 2.6 to 18.5 days) in 4 (9%; 95% CI, 2% to 21%) FN episodes, usually for per-
sisting fever5 days. Virtually applying LimitStandard (39.0˚C) as TLDF for persisting fever
resulted in the addition of an intravenous empirical antifungal therapy in 6 episodes (13%; 5%
to 27%; plus 2 episodes compared to reality) after a median of 161 hours (6.7 days). Virtually
applying a range of LimitLow, increased the number of such episodes to 10 (22%; plus 6) for
38.5˚C, to 11 (24%; plus 7) for 38.0˚C, and to 14 (31%; plus 10) for 37.5˚C. (Fig 3, Table 1).
One further patient with AML had received an intravenous antifungal therapy with caspofun-
gin intravenously (iv) at presentation with FN in addition to the empiric antibiotics as Candida
albicans had been cultured 6 days before FN diagnosis from both skin and oral swabs.
Delayed discharge
In the entire set of 45 FN episodes, the median duration of hospitalization was 5.7 days (IQR,
3.1 to 8.8; range, 0.8 to 43). In the 40 episodes analyzed for delayed discharge (at least one tem-
perature measurement 39.0˚C, no early discharge < 24 hours), the median duration was 0.8
hours (IQR, 0 to 22.6, range, 0 to 172.4) when applying a TLDF of 38.5˚C instead of 39.0˚C. In
these 40 episodes, virtually applying a range of different LimitLow, resulted in 12 FN episodes
with discharge delay 12 hours for 38.5˚C (30%; median delay 1 hour; IQR, 0 to 22; range, 0
to 172); in 21 episodes for 38.0˚C (53%; median delay 13 hours; IQR, 1 to 35; range, 0 to 172),
and in 32 episodes for 37.5˚C (80%; median delay 37 hours; IQR, 13 to 75; range, 0 to 286) (Fig
4, Table 1).
Table 1. Management of FN episodes diagnosed in reality, and virtually at different temperature limits defining fever.
Type of analysis, item FN diagnosed in reality FN virtually diagnosed using limitStandard or limitLow
39.0˚C 38.5˚C 38.0˚C 37.5˚C
FN episodes with additional BC taken1 31 22 29 33 38
Number of additional BC taken1 77 43 68 103 148
FN episodes with escalation of empirical antibiotics2 22 15 22 26 34
Median time-point of escalation of empirical antibiotic’s (hours) 49 74 69 56 53
FN episodes with addition of antifungal therapy3 4 6 10 11 14
Number of antifungal therapies added3 5 10 15 19 23
Median time of addition of antifungal therapy (hours) 177 161 138 129 127
FN episodes with delayed hospital discharge12h - 0 12 21 32
Median delay of hospital discharge (hours) - 0 1 13 37
Cumulative delay of hospital discharge (hours) - 0 832 1295 2312
FN, fever in neutropenia; BC, blood cultures.
1for persisting fever 24h after start of antibiotics;
2for persisting fever 48h after start of antibiotics;
3for persisting fever 120h after start of antibiotics
https://doi.org/10.1371/journal.pone.0193227.t001
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Discussion
The efficacy of a high versus low TLDF in patients with chemotherapy induced neutropenia
has been shown to significantly reduce the number of emergency calls for fever, of performed
CBCs and of overall FN diagnosis [7]. The results presented here further demonstrate its effi-
cacy by significant and clinically relevant reductions of both diagnostic (additional BCs) and
therapeutic measures (escalation of empirical antibiotics, addition of empirical antifungal ther-
apy, length of hospital stay) after the diagnosis of FN has been made. These reductions, in
return, stand for less side effects, less treatment costs and a better quality of life for the patient
and his family [8,21].
Strictly applying a high TLDF of 39.0˚C, irrespective of the clinical condition, would have
halved the number of additional BC taken after start of antimicrobial therapy. As one third of
the bacteremia was detected in such additional BC, both a strict application of this LimitStandard
or a further increase of this TLDF would lead to delayed or missed diagnoses of bacteremia in
a relevant proportion of FN, with potentially detrimental clinical consequences. In reality, the
treating physician was free to ask for additional BC below this Limitstandard when clinically
indicated, which reduced this risk and maintained clinical safety. As previously shown, half of
the reported adverse events (AEs) were detected in episodes diagnosed below 39.0˚C; so within
an oncology center, it has to be assured, that every treating physician is aware about this fact
and that the Limitstandard should be considered as a guidance and not as a rule carved in stone.
This once more, underlines the importance of clinical judgement overrating a predefined
TLDF when needed.
Taken together, in reality a relevant number of FN episodes was diagnosed below LimitStandard
[7] and diagnostics were frequently escalated by additional BC below LimitStandard as well. In line
with this, empirical antibiotics were as well frequently escalated below LimitStandard for clinical
reasons. In sharp contrast to these three consistent observations, escalation of therapy by adding
empirical antifungals was less frequently observed in reality than defined by strict application of
LimitStandard. Interestingly, this inversely oriented discrepancy reflects the importance of clinical
judgment as well. Here the treating physician refrained from adding antifungals in patients with-
out high risk for invasive fungal infection and in good general condition despite prolonged fever
LimitStandard, consistent with past and current guidelines [1,15].
Fig 4. Discharge delay according to TLDF. Displayed are proportions of FN episodes (filled red circles) with their
95% CI (vertical lines) and the median delay of all episodes in hours (filled blue circle).
https://doi.org/10.1371/journal.pone.0193227.g004
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In one third of FN episodes, lowering the TLDF from 39.0˚ C to 38.5˚ C would have resulted
in a delay in hospital discharge exceeding 12 hours.
The calculated discharge delays are additionally underestimated due to incomplete record-
ings beyond 48 hours from the last temperatures39.0˚C because, in reality, patients were dis-
charged. Correspondingly, lowering the TLDF would have resulted in relevant cost increase.
To our knowledge, this is the first prospective, though purely observational, study of the
influence of different fever definitions on diagnostics and treatment after the diagnosis of fever
in chemotherapy-induced neutropenia in children with cancer.
The findings of this study are based on large numbers of prospectively recorded tempera-
ture measurements. The in silicon simulation allowed for a non-interventional study. This
study critically relied on the high standard TLDF of 39.0˚C used in Bern. A reverse design, i.e.,
virtually assessing the impact of higher TLDFs in centers using low or medium TLDFs, is
made impossible by the routine application of antipyretics after FN diagnosis. Potential limita-
tions are its single center design. Besides, the rather small sample size, powered for efficacy
testing of the primary outcome, FN diagnosis [7], precluded meaningful assessment of safety
aspects. Currently, the randomized controlled multicenter Swiss Pediatric Oncology Group
(SPOG) 2015 FN Definition trial, powered to assess the safety of a high (39.0˚C) versus low
(38.5˚C) TLDF, is recruiting patients (NCT02324231).
In conclusion, this study shows that a high versus low TLDF is efficacious in reducing diag-
nostic measures, both antibacterial and antifungal antimicrobial therapy and length of hospital
stay in children and adolescents with FN during chemotherapy for cancer. Significant and
clinically relevant differences in all these measures have been shown for a TLDF of 39.0˚C
versus 38.5˚C. Applying a high TLDF thus may decrease treatment-related side effects and
costs and increase the quality of life. The differences between the clinical management found
in reality versus the virtual management based on strictly applying LimitStandard underlines the
importance of clinical judgement by experienced pediatric oncologists.
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